Carl Zeiss AFX.DE · XETRA
35.44 € -0.28% (-0.10 €)
Summary
60 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It could repay all its net debt from 0.0 years of operating profit.
What to watch
- Earnings per share fell by 21% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.2 EUR for 1 EUR of yearly profit. Over the last five years it was 36.5 EUR on average.
Valuation in detailIs it growing?
SlowlyRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 5.4% a year. For the next fiscal year analysts expect revenue to fall by 2.3%. Earnings per share fell by 21% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 49 EUR
- Research and development 16 EUR
- Sales and administration 29 EUR
- Taxes and other 2.0 EUR
- Net profit 4.4 EUR
Net profit, industry median (Medical - Instruments & Supplies) 8.1 EUR
Out of every 100 EUR of revenue, 4.4 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.58%
- Paid out of profit
- 41%
You receive 0.55 € per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail